PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27687548-10 2016 Indomethacin, diclofenac, and meloxicam highly upregulated radiation-induced expression of ICAM-1 and COX-2. Meloxicam 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 102-107 29174987-2 2018 MLX has a preferential affinity for COX-2, which is associated with a lower incidence of gastrointestinal side effects. Meloxicam 0-3 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 27479158-13 2016 In this comparative study, the administration of the preferential COX-2 inhibitor Meloxicam via histidine-tryptophan-ketoglutarate showed the best graft-protective attributes and the lowest hepatotoxic side effects. Meloxicam 82-91 mitochondrially encoded cytochrome c oxidase II Homo sapiens 66-71 27687548-0 2016 NSAIDs diclofenac, indomethacin, and meloxicam highly upregulate expression of ICAM-1 and COX-2 induced by X-irradiation in human endothelial cells. Meloxicam 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 90-95 32721780-6 2020 Moreover, every examined derivative of pyrrolo[3,4-d]pyridazinone demonstrates better inhibitory activity towards COX-2 and a superior COX-2/COX-1 selectivity ratio compared to the reference drug meloxicam. Meloxicam 196-205 mitochondrially encoded cytochrome c oxidase II Homo sapiens 114-119 32721780-6 2020 Moreover, every examined derivative of pyrrolo[3,4-d]pyridazinone demonstrates better inhibitory activity towards COX-2 and a superior COX-2/COX-1 selectivity ratio compared to the reference drug meloxicam. Meloxicam 196-205 mitochondrially encoded cytochrome c oxidase II Homo sapiens 135-140 29030657-2 2017 There are limited studies assessing the risk of MI associated with meloxicam, an increasingly popular drug with COX-2 inhibiting properties. Meloxicam 67-76 mitochondrially encoded cytochrome c oxidase II Homo sapiens 112-117 28353025-7 2017 The traditional NSAIDs (i.e., meloxicam, etodolac, and nabumetone) have significant COX-2 specificity, but naproxen and ibuprofen have less specificity. Meloxicam 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 84-89 27523985-6 2016 Moreover, selective COX-2 inhibitor NSAIDs, such as meloxicam or parecoxib, were advantageous over the non-selective COX-1 and COX-2 inhibitor NSAIDs lornoxicam and diclofenac. Meloxicam 52-61 mitochondrially encoded cytochrome c oxidase II Homo sapiens 20-25 27687548-13 2016 CONCLUSION: Indomethacin, diclofenac, and meloxicam highly upregulated radiation-induced expression of ICAM-1 and COX-2 in HUVECs, which suggests that use of these NSAIDs may increase the effects of ionizing radiation and affect the risk of MI after radiation exposure to the heart. Meloxicam 42-51 mitochondrially encoded cytochrome c oxidase II Homo sapiens 114-119 25429611-3 2016 The aim of the present study was to determine the effects of a cyclo-oxygenase (COX)-2 inhibitor (meloxicam) on gonadotropin-releasing hormone (GnRH) and LH secretion in anoestrous ewes during systemic inflammation induced by LPS. Meloxicam 98-107 mitochondrially encoded cytochrome c oxidase II Homo sapiens 63-86 27109804-0 2016 Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the beta-catenin signaling pathway. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 92-97 27109804-3 2016 Meloxicam is a selective COX-2 inhibitor that has been reported to exert an anti-proliferation and invasion/migration response in various tumors. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-30 27109804-6 2016 Furthermore, meloxicam suppressed the ability of HCC cells expressing higher levels of COX-2 and prostaglandin E2 (PGE2) to migration via potentiating expression of E-cadherin and alleviating expression of matrix metalloproteinase (MMP)-2 and -9. Meloxicam 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 87-92 25515365-0 2015 The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Meloxicam 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 26826540-7 2016 Prophylactic administration of meloxicam, a preferential inhibitor of COX-2 activity, prevented both central inflammation and deficits in affective-like behaviors. Meloxicam 31-40 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 25899770-2 2015 PATIENTS AND METHODS: Since March 2003, patients pathologically diagnosed with extraperitoneal desmoid tumors have been prospectively treated with meloxicam, a COX-2 inhibitor, at our institution. Meloxicam 147-156 mitochondrially encoded cytochrome c oxidase II Homo sapiens 160-165 26600514-3 2015 In the present study, the ability of meloxicam, a COX-2-specific inhibitor to enhance doxorubicin-mediated inhibition was investigated in human A549 lung cancer in vivo and in vitro. Meloxicam 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 50-55 26600514-7 2015 The results reported in the present study demonstrate for the first time that the specific COX-2 inhibitor meloxicam can increase the intracellular accumulation of doxorubicin and enhance doxorubicin-induced cytotoxicity in A549 cancer cells by reducing the expression of MRP1 and MRP4. Meloxicam 107-116 mitochondrially encoded cytochrome c oxidase II Homo sapiens 91-96 24425867-2 2014 Isoxicam is a nonselective inhibitor of COX-1 and COX-2 whereas meloxicam displays some selectivity for COX-2. Meloxicam 64-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 104-109 24675684-0 2014 Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2- dependent and -independent pathways. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 77-82 24675684-2 2014 Meloxicam, a selective COX-2 inhibitor, has shown potential therapeutic effects against HCC, but the mechanisms accounting for its anti-cancer activities remain unclear. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 23-28 25271421-5 2014 Subsequently, we tested the ability of meloxicam, a selective COX-2 inhibitor, to attenuate behavioral deficits via inflammatory mechanisms. Meloxicam 39-48 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 25255073-1 2014 Meloxicam is a commonly used COX2-preferential NSAID in both human and veterinary patients. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-33 24675684-3 2014 METHODS AND FINDINGS: Meloxicam inhibited the ability of human HCC cells expressing higher levels of COX-2 to migrate, invade, adhere and form colonies through upregulating the expression of E-cadherin and downregulating the expression of matrix metalloproteinase (MMP) -2. Meloxicam 22-31 mitochondrially encoded cytochrome c oxidase II Homo sapiens 101-106 24675684-5 2014 Addition of prostaglandin E2 (PGE2), the major product of COX-2, could abrogate the effects of meloxicam on the expression of survivin and myeloid cell leukemia-1 (Mcl-1), but not Bax and Fas-L, indicating that meloxicam induces cell apoptosis via both COX-2-dependent and -independent pathways. Meloxicam 95-104 mitochondrially encoded cytochrome c oxidase II Homo sapiens 58-63 24675684-5 2014 Addition of prostaglandin E2 (PGE2), the major product of COX-2, could abrogate the effects of meloxicam on the expression of survivin and myeloid cell leukemia-1 (Mcl-1), but not Bax and Fas-L, indicating that meloxicam induces cell apoptosis via both COX-2-dependent and -independent pathways. Meloxicam 95-104 mitochondrially encoded cytochrome c oxidase II Homo sapiens 253-258 24675684-5 2014 Addition of prostaglandin E2 (PGE2), the major product of COX-2, could abrogate the effects of meloxicam on the expression of survivin and myeloid cell leukemia-1 (Mcl-1), but not Bax and Fas-L, indicating that meloxicam induces cell apoptosis via both COX-2-dependent and -independent pathways. Meloxicam 211-220 mitochondrially encoded cytochrome c oxidase II Homo sapiens 58-63 24675684-8 2014 CONCLUSIONS: Meloxicam executes its antitumor effects by targeting the COX-2/MMP-2/E-cadherin, AKT, apoptotic and autophagic pathways in COX-2-dependent and -independent pathways, and inhibition of cell autophagy could help to overcome the resistance to meloxicam-induced apoptosis in HCC. Meloxicam 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-76 24675684-8 2014 CONCLUSIONS: Meloxicam executes its antitumor effects by targeting the COX-2/MMP-2/E-cadherin, AKT, apoptotic and autophagic pathways in COX-2-dependent and -independent pathways, and inhibition of cell autophagy could help to overcome the resistance to meloxicam-induced apoptosis in HCC. Meloxicam 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 137-142 24675684-8 2014 CONCLUSIONS: Meloxicam executes its antitumor effects by targeting the COX-2/MMP-2/E-cadherin, AKT, apoptotic and autophagic pathways in COX-2-dependent and -independent pathways, and inhibition of cell autophagy could help to overcome the resistance to meloxicam-induced apoptosis in HCC. Meloxicam 254-263 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-76 24425867-3 2014 Here we report crystal complexes of COX-2 with isoxicam and meloxicam at 2.0 and 2.45 angstroms, respectively, and a crystal complex of COX-1 with meloxicam at 2.4 angstroms. Meloxicam 60-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 24425867-8 2014 In addition, a detailed study of meloxicam COX-2 interactions revealed that mutation of Val-434 to Ile significantly reduces inhibition by meloxicam due to subtle changes around Phe-518, giving rise to the preferential inhibition of COX-2 over COX-1. Meloxicam 33-42 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 24425867-8 2014 In addition, a detailed study of meloxicam COX-2 interactions revealed that mutation of Val-434 to Ile significantly reduces inhibition by meloxicam due to subtle changes around Phe-518, giving rise to the preferential inhibition of COX-2 over COX-1. Meloxicam 139-148 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 24425867-8 2014 In addition, a detailed study of meloxicam COX-2 interactions revealed that mutation of Val-434 to Ile significantly reduces inhibition by meloxicam due to subtle changes around Phe-518, giving rise to the preferential inhibition of COX-2 over COX-1. Meloxicam 139-148 mitochondrially encoded cytochrome c oxidase II Homo sapiens 233-238 20580659-6 2010 S.c. treatment with the preferential COX-2 inhibitor meloxicam attenuated, but not abolished fever induced by local injections of MALP-2 into the pouch. Meloxicam 53-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 23298324-11 2014 Plasma concentration of meloxicam was maintained above its IC50 concentration required for COX-2 inhibition for 23 days. Meloxicam 24-33 mitochondrially encoded cytochrome c oxidase II Homo sapiens 91-96 23031659-8 2013 COX-2 inhibitors were well tolerated in the majority of the patients [nimesulide: 91.9%; meloxicam: 90.2%; rofecoxib: 94.9%; and celecoxib: 94.9%)]. Meloxicam 89-98 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 23480764-3 2012 Thus, the aim of this study was to examine the effects of two anti-inflammatory agents, meloxicam, a selective COX-2 inhibitor, and xanthohumol, a natural plant extract, on PGE2 production and migration ability of human CCA cell lines. Meloxicam 88-97 mitochondrially encoded cytochrome c oxidase II Homo sapiens 111-116 22348284-3 2012 OBJECTIVE: In this study, meloxicam, which is an enolic acid-type preferential COX-2 inhibitor, was encapsulated in poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles (NPs) to maintain local high concentration, and its efficacy was determined. Meloxicam 26-35 mitochondrially encoded cytochrome c oxidase II Homo sapiens 79-84 24213228-2 2012 The treatment modality in our institutions before 2003 was surgical resection with wide surgical margin, however, meloxicam, which is a NSAID and a selective COX-2 inhibitor has been applied consecutively since 2003. Meloxicam 114-123 mitochondrially encoded cytochrome c oxidase II Homo sapiens 158-163 20840388-9 2010 In contrast, meloxicam (0.3 mg/kg via subcutaneous injection) inhibited both COX-1 and COX-2 isoforms significantly for at least 24 h, indicating nonselectivity in vivo. Meloxicam 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 87-92 20651346-4 2010 Following stimulation with different concentrations of the selective COX-2 inhibitor meloxicam, apoptosis was assessed immunohistochemically after 6 h and 12 h. All primary carcinomas and 56 out of the 57 liver metastases showed various degrees of cytoplasmatic COX-2 expression being with a reduction and in the liver metastases. Meloxicam 85-94 mitochondrially encoded cytochrome c oxidase II Homo sapiens 69-74 19709125-2 2009 We have previously reported that kallistatin gene therapy suppressed the growth of HCC tumors by its anti-angiogenic activity, and meloxicam, a selective COX-2 inhibitor, inhibited proliferation and induced apoptosis of human HCC cells in vitro. Meloxicam 131-140 mitochondrially encoded cytochrome c oxidase II Homo sapiens 154-159 19963049-1 2010 Recent studies have shown that COX-2 inhibitors, such as meloxicam, have demonstrated promising results when used with chemotherapy. Meloxicam 57-66 mitochondrially encoded cytochrome c oxidase II Homo sapiens 31-36 19602986-4 2009 The hazard might also extend to traditional NSAIDs, which are relatively selective for COX-2, such as diclofenac, meloxicam, and etodolac. Meloxicam 114-123 mitochondrially encoded cytochrome c oxidase II Homo sapiens 87-92 18403118-5 2008 Here, we show that COX-2 induces dopamine oxidation, as evidenced by the findings that COX-2 can facilitate dopamine oxidation in a cell-free system and in COX-2-overexpressing SH-SY5Y cells, and that this can be completely abolished by the selective COX-2 inhibitor meloxicam. Meloxicam 267-276 mitochondrially encoded cytochrome c oxidase II Homo sapiens 19-24 19203564-1 2009 A novel topical ophthalmic formulation of the preferential COX-2 inhibitor meloxicam has recently been developed. Meloxicam 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 59-64 19642502-7 2009 In this patient meloxicam treatment, a preferential selective COX-2 inhibitor, leaded to a significant reduction in the number of colorectal polyps during 3 years follow up. Meloxicam 16-25 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 18499296-3 2009 Based on these observations, we assessed the efficacy and tolerability of the combination chemotherapy consisting of carboplatin and paclitaxel with meloxicam, a selective COX-2 inhibitor. Meloxicam 149-158 mitochondrially encoded cytochrome c oxidase II Homo sapiens 172-177 18403118-5 2008 Here, we show that COX-2 induces dopamine oxidation, as evidenced by the findings that COX-2 can facilitate dopamine oxidation in a cell-free system and in COX-2-overexpressing SH-SY5Y cells, and that this can be completely abolished by the selective COX-2 inhibitor meloxicam. Meloxicam 267-276 mitochondrially encoded cytochrome c oxidase II Homo sapiens 87-92 18403118-5 2008 Here, we show that COX-2 induces dopamine oxidation, as evidenced by the findings that COX-2 can facilitate dopamine oxidation in a cell-free system and in COX-2-overexpressing SH-SY5Y cells, and that this can be completely abolished by the selective COX-2 inhibitor meloxicam. Meloxicam 267-276 mitochondrially encoded cytochrome c oxidase II Homo sapiens 87-92 18403118-5 2008 Here, we show that COX-2 induces dopamine oxidation, as evidenced by the findings that COX-2 can facilitate dopamine oxidation in a cell-free system and in COX-2-overexpressing SH-SY5Y cells, and that this can be completely abolished by the selective COX-2 inhibitor meloxicam. Meloxicam 267-276 mitochondrially encoded cytochrome c oxidase II Homo sapiens 87-92 15827035-2 2005 In 2001, the National Institute for Clinical Excellence (NICE) published guidance on the use of the COX-2 agents celecoxib, rofecoxib, meloxicam and etodolac for rheumatoid arthritis (RA) and osteoarthritis (OA). Meloxicam 135-144 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-105 19024285-5 2008 Meloxicam is COX-2 selective NSAID with favourable gastrointestinal and thromboembolic safety profile. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 17340600-7 2007 Responses to fluid-induced shear were blocked by the general Cox inhibitor indomethacin and the Cox-2 inhibitor meloxicam, indicating that response to shear is mediated by prostaglandin produced via a Cox-2 dependent mechanism. Meloxicam 112-121 mitochondrially encoded cytochrome c oxidase II Homo sapiens 96-101 17340600-7 2007 Responses to fluid-induced shear were blocked by the general Cox inhibitor indomethacin and the Cox-2 inhibitor meloxicam, indicating that response to shear is mediated by prostaglandin produced via a Cox-2 dependent mechanism. Meloxicam 112-121 mitochondrially encoded cytochrome c oxidase II Homo sapiens 201-206 17164136-4 2007 In contrast, the tNSAIDs meloxicam, nimesulide and diclofenac (which are from 18- to 29-fold more potent towards COX-2 in vitro) and coxibs (i.e. celecoxib, valdecoxib, rofecoxib, etoricoxib and lumiracoxib, which are from 30- to 433-fold more potent towards COX-2 in vitro) should be comprised into the cluster of COX-2 inhibitors. Meloxicam 25-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 113-118 16863437-5 2005 At the FDA-recommended doses meloxicam is COX-2 preferential. Meloxicam 29-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 16358608-8 2005 A transient elevation of c-Fos and c-Jun messenger RNAs was induced by TNF-alpha, whereas COX-2 inhibitors NS-398 and meloxicam abolished the up-regulation of c-Fos. Meloxicam 118-127 mitochondrially encoded cytochrome c oxidase II Homo sapiens 90-95 16197363-2 2005 Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class, and is a preferential inhibitor of COX-2, demonstrating effectiveness with anti-inflammatory, analgesic and antipyretic activity. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 116-121 18058818-0 2008 The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo. Meloxicam 33-42 mitochondrially encoded cytochrome c oxidase II Homo sapiens 17-22 18058818-2 2008 The purpose of this study was to determine if similar changes occurred in vivo in the tumors of patients with SCC of the esophagus who were given a preferential COX-2 inhibitor, meloxicam. Meloxicam 178-187 mitochondrially encoded cytochrome c oxidase II Homo sapiens 161-166 18058818-13 2008 We conclude that meloxicam induces apoptosis in SCC of the esophagus in vivo by inhibiting the pathway of NF-kappaB downstream regulation of COX-2. Meloxicam 17-26 mitochondrially encoded cytochrome c oxidase II Homo sapiens 141-146 18516356-10 2008 The older NSAIDs, such as meloxicam, with preferential COX-2 inhibition do not have good long-term evidence of reducing the incidence of serious gastrointestinal complications. Meloxicam 26-35 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-60 17447009-0 2007 Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells. Meloxicam 78-87 mitochondrially encoded cytochrome c oxidase II Homo sapiens 61-66 17447009-4 2007 In this study, the effects of the selective COX-2 inhibitor meloxicam alone and in combination with irradiation were investigated on human glioma cells in vitro. Meloxicam 60-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-49 17447009-10 2007 The selective COX-2 inhibitor meloxicam exerted COX-2 independent growth inhibition and radiosensitization of human glioma cells. Meloxicam 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 17447009-10 2007 The selective COX-2 inhibitor meloxicam exerted COX-2 independent growth inhibition and radiosensitization of human glioma cells. Meloxicam 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 17017983-1 2006 Meloxicam was launched as a major new NSAID for the treatment of arthritis following extensive published research confirming its selectivity for COX-2. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 145-150 17017983-11 2006 In contrast lornoxicam and meloxicam, which demonstrated activity against COX-2, have revealed smaller partition capacity in liposomes/water systems together with a higher ability to change the membrane fluidity and surface potential. Meloxicam 27-36 mitochondrially encoded cytochrome c oxidase II Homo sapiens 74-79 16462098-1 2006 Meloxicam (MLX), a non-steroidal anti-inflammatory drug (NSAID) and a selective COX-2 inhibitor is a water insoluble drug (about 12 microg/ml). Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 80-85 17154669-6 2006 Preferential COX-2 inhibitors (nimesulide, meloxicam) are tolerated by the majority but not all hypersensitive patients. Meloxicam 43-52 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 15892673-5 2005 Selective cyclooxygenase-2 (COX-2) inhibitors represent a new group of pharmaceutical products termed "coxibs" that include meloxicam, nimesulide, etodolac and celecoxib. Meloxicam 124-133 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 16021964-0 2005 [The selective cox-2 inhibitor meloxicam and salicylate therapy]. Meloxicam 31-40 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 12553505-1 2002 We performed a randomized, prospective study on the prophylaxis of heterotopic ossification (HO) after total hip arthroplasty (THR), comparing indomethacin and the selective COX-2 inhibitor meloxicam. Meloxicam 190-199 mitochondrially encoded cytochrome c oxidase II Homo sapiens 174-179 16180941-3 2005 OBJECTIVE: The objective of this study is to review cases of Stevens-Johnson syndrome and toxic epidermal necrolysis reported to the FDA associated with the use of the selective COX-2 inhibitor NSAIDs celecoxib, rofecoxib and valdecoxib, and to compare reporting rates of the two conditions associated with these drugs to each other, meloxicam (an oxicam NSAID that came on the US market at a similar time) and the background incidence rate. Meloxicam 334-343 mitochondrially encoded cytochrome c oxidase II Homo sapiens 178-183 15329003-3 2004 OBJECTIVE: The aim of this study was to evaluate the tolerability of three COX-2 inhibitors (meloxicam, celecoxib and rofecoxib) in subjects with previous pseudoallergic respiratory and cutaneous reactions to NSAIDs. Meloxicam 93-102 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 14606784-0 2003 Evaluation of meloxicam (A cox-2 inhibitor) for management of postoperative endodontic pain: a double-blind placebo-controlled study. Meloxicam 14-23 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 12711837-9 2003 Etodolac and meloxicam showed selectivity for human COX-2 over COX-1. Meloxicam 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 52-57 12401798-10 2002 Two selective COX-2 inhibitors, meloxicam and NS398, decreased HIF-1alpha levels and nuclear localization, under both normoxic and hypoxic conditions. Meloxicam 32-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 15673949-1 2004 AIM: to know the effect of piroxicam (COX-1 and COX-2 inhibitor NSAID) and meloxicam (selective COX-2 inhibitor NSAID) against the gastric mucosa. Meloxicam 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 96-101 15242723-3 2004 Partial inhibitors of both COX-1 and COX-2, such as nimesulide and meloxicam, also cross-react but only at high drug doses. Meloxicam 67-76 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 15199082-1 2004 This study determined if meloxicam, a selective cyclooxygenase (COX)-2 inhibitor, interferes with the antiplatelet effect of aspirin using platelet aggregation and thromboxane (Tx) B(2) endpoints in healthy volunteers. Meloxicam 25-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-70 14991771-3 2004 bFGF reduced apoptosis in MCF-7 breast cancer cells and up-regulated the expression of mitocondrial Bcl-2, whereas COX inhibitors meloxicam (selective COX-2) and aspirin (non-selective), induced apoptosis. Meloxicam 130-139 mitochondrially encoded cytochrome c oxidase II Homo sapiens 151-156 12549993-10 2003 A pilot study was carried out in 120 patients with acute coronary syndrome without ST-segment elevation in which 60 patients were treated with meloxicam, a preferential COX-2 inhibitor. Meloxicam 143-152 mitochondrially encoded cytochrome c oxidase II Homo sapiens 169-174 12508788-0 2002 A selective COX-2 inhibitor, meloxicam, as a treatment option in patients with juvenile idiopathic arthritis and gastrointestinal side effects from naproxen. Meloxicam 29-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 12-17 12387696-3 2002 Meloxicam has been shown to be COX-2 preferential, particularly at its lowest therapeutic dose, and is anti-inflammatory by inhibiting prostanoid synthesis in inflammatory cells. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 31-36 12162776-8 2002 Meloxicam (a specific COX-2 inhibitor) suppressed the induction of cytokines on IL-6 mRNA levels, and these effects could be reversed by exogenous prostaglandin E(2). Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 12022326-1 2002 OBJECTIVE: Use of meloxicam as a selective COX-2 inhibitor for treatment of adult rheumatic diseases decreases the frequency of gastrointestinal (GI) side effects in comparison with nonselective COX inhibitors. Meloxicam 18-27 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 12162470-2 2002 Meloxicam is a relatively COX-2-selective anti-arthritis drug that shows significant TxA2 inhibition, albeit less than traditional NSAIDs. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-31 11874389-7 2002 The ratios of IC50s and, at best, of IC80s revealed diclofenac and meloxicam as selective COX-2 inhibitors and ibuprofen as a preferential COX-1 inhibitor in vitro. Meloxicam 67-76 mitochondrially encoded cytochrome c oxidase II Homo sapiens 90-95 11961179-3 2002 OBJECTIVE: To compare the effects of the COX-2-selective inhibitor, meloxicam, with those of the non-selective NSAID, naproxen, on platelet function and thromboxane levels in RA patients. Meloxicam 68-77 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 11570615-6 2001 Reaction rates for COX-2 inhibitors were 21.3% for nimesulide, 17.3% for meloxicam, 33.3% for celecoxib, and 3.0% for rofecoxib. Meloxicam 73-82 mitochondrially encoded cytochrome c oxidase II Homo sapiens 19-24 11825322-5 2001 However, the older drugs etodolac, nimesulide and meloxicam, made before COX-2 was discovered, are also COX-1-sparing and have good GI safety and therapeutic activities. Meloxicam 50-59 mitochondrially encoded cytochrome c oxidase II Homo sapiens 73-78 11566042-5 2001 Others, such as meloxicam, may inhibit COX-2 by different mechanisms. Meloxicam 16-25 mitochondrially encoded cytochrome c oxidase II Homo sapiens 39-44 11503270-4 2001 Selective COX-2 inhibitors i.e. meloxicam, nimesulid, etodolac or highly selective COX-2 inhibitors i.e. celecoxib, rofecoxib have antiinflammatory and analgesic properties with less or no gastrointestinal or other NSAIDs-typical adverse effects. Meloxicam 32-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 11062695-2 2000 Meloxicam (preferential COX-2 inhibitor) inhibits the growth of COX-2 positive and COX-1 negative colorectal cancer cells. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 11078056-8 2000 Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1. Meloxicam 36-45 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 11078056-8 2000 Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1. Meloxicam 36-45 mitochondrially encoded cytochrome c oxidase II Homo sapiens 166-171 11078056-9 2000 For instance, meloxicam inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express COX-2 but has no effect on HCT-116 tumor cells that do not express COX-2. Meloxicam 14-23 mitochondrially encoded cytochrome c oxidase II Homo sapiens 108-113 11062695-2 2000 Meloxicam (preferential COX-2 inhibitor) inhibits the growth of COX-2 positive and COX-1 negative colorectal cancer cells. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 64-69 10848664-7 2000 In the whole blood assays, the COX-2/COX-1 ratio for meloxicam was 0.2 compared to 0.9 for indomethacin confirming meloxicam"s COX-2 selectivity. Meloxicam 115-124 mitochondrially encoded cytochrome c oxidase II Homo sapiens 31-36 10977130-6 2000 Meloxicam in the same assay showed COX-2 selectivity with a ratio of 0.19. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 35-40 10848664-7 2000 In the whole blood assays, the COX-2/COX-1 ratio for meloxicam was 0.2 compared to 0.9 for indomethacin confirming meloxicam"s COX-2 selectivity. Meloxicam 115-124 mitochondrially encoded cytochrome c oxidase II Homo sapiens 127-132 10848664-3 2000 AIM: To compare prostaglandin synthesis inhibition by meloxicam, a selective COX-2 NSAID reported to have better gastric tolerability, with indomethacin and NS-398 in human gastric mucosa and in whole blood assays. Meloxicam 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 77-82 10848664-7 2000 In the whole blood assays, the COX-2/COX-1 ratio for meloxicam was 0.2 compared to 0.9 for indomethacin confirming meloxicam"s COX-2 selectivity. Meloxicam 53-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 31-36 10718662-1 2000 A simple, HPLC method was developed to estimate meloxicam (COX-2 inhibitor) using piroxicam as the internal standard. Meloxicam 48-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 59-64 10628593-8 1999 Patients using meloxicam experienced less dyspepsia (odds ratio = 0.73; 95% CI, 0.64-0.84), fewer PUBs (odds ratio = 0.52; 95% CI, 0.28-0.96), and less frequent discontinuation of NSAID because of adverse GI events (odds ratio = 0.59; 95% CI, 0.52-0.67) compared with non-COX-2 selective NSAIDs. Meloxicam 15-24 mitochondrially encoded cytochrome c oxidase II Homo sapiens 272-277 11153163-11 2000 Nimesulide and meloxicam selectively block COX-2 and are recommended to patients at risk or treated with diuretics. Meloxicam 15-24 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 10628593-9 1999 Meloxicam, a COX-2-selective NSAID, appears to cause fewer adverse GI events than standard, non-COX-2-selective NSAIDs. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 10381787-1 1999 We evaluated whether therapeutic blood levels of meloxicam are associated with selective inhibition of monocyte cyclooxygenase (COX)-2 in vitro and ex vivo. Meloxicam 49-58 mitochondrially encoded cytochrome c oxidase II Homo sapiens 112-134 10381787-2 1999 Concentration-response curves for the inhibition of monocyte COX-2 and platelet COX-1 were obtained in vitro after the incubation of meloxicam with whole blood samples. Meloxicam 133-142 mitochondrially encoded cytochrome c oxidase II Homo sapiens 61-66 10381787-8 1999 In contrast, the administration of 7.5 and 15 mg of meloxicam caused dose-dependent reductions in monocyte COX-2 activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively. Meloxicam 52-61 mitochondrially encoded cytochrome c oxidase II Homo sapiens 107-112 9783757-6 1998 The Meloxicam Large-scale International Study Safety Assessment (MELISSA) trial reported here was therefore set up to investigate the tolerability of meloxicam, a preferential inhibitor of COX-2, compared to diclofenac. Meloxicam 150-159 mitochondrially encoded cytochrome c oxidase II Homo sapiens 189-194 9831330-3 1998 Standard non-steroidal anti-inflammatory drugs can be considered nonselective; compounds such as meloxicam and nimesulide can be classified as COX-2 preferential; and compounds such as SC 58125 and L-754,337 are selective for COX-2. Meloxicam 97-106 mitochondrially encoded cytochrome c oxidase II Homo sapiens 143-148 9831331-3 1998 Meloxicam, etodolac and diclofenac also showed high COX-2 selectivity. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 52-57 10381057-14 1999 Meloxicam was a more potent inhibitor of COX-2 (IC50 = 4.7 microM) than aspirin (IC50 = 29.3 microM) and similar to piroxicam (IC50 = 4.4 microM). Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 10381057-15 1999 Among all drugs tested dexamethasone showed the greatest selectivity for COX-2 and meloxicam was the NSAID with the best COX-2/COX-1 ratio (r = 0.12). Meloxicam 83-92 mitochondrially encoded cytochrome c oxidase II Homo sapiens 121-126 10340919-1 1999 OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by meloxicam, which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2). Meloxicam 82-91 mitochondrially encoded cytochrome c oxidase II Homo sapiens 161-166 10391112-4 1999 Finally, the latest published clinical data of new selective and highly selective inhibitors of COX-2 (meloxicam, nimesulide, etodolac, celecoxib and MK966) are discussed. Meloxicam 103-112 mitochondrially encoded cytochrome c oxidase II Homo sapiens 96-101 19078322-4 1998 Meloxicam was investigated in several in vitro test systems in which it consistently demonstrated preferential COX-2 inhibition. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 111-116 19078323-3 1998 Newer inhibitors such as meloxicam, which have been shown to inhibit COX-2 preferentially in vitro, are expected to retain their efficacy while exhibiting decrease toxicity. Meloxicam 25-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 69-74 19078323-8 1998 These data confirm that preferential COX-2 inhibitors such as meloxicam provide a significant advantage over standard NSAIDs in the treatment of rheumatic diseases. Meloxicam 62-71 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 9783757-24 1998 These results may in part reflect the preferential COX-2 selectivity of meloxicam, although the dose and other aspects of tolerability may be important. Meloxicam 72-81 mitochondrially encoded cytochrome c oxidase II Homo sapiens 51-56 9783758-0 1998 Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Meloxicam 96-105 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-84 9475035-17 1997 Recently drugs such as nimesulide and meloxicam with selective action on COX-2 have been discovered and introduced into medicine. Meloxicam 38-47 mitochondrially encoded cytochrome c oxidase II Homo sapiens 73-78 9737091-13 1998 CONCLUSION: Meloxicam inhibited furosemide stimulated renin release, suggesting that in man COX-2 is responsible for prostaglandin synthesis mediating renin release. Meloxicam 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 92-97 9553452-2 1998 Meloxicam is a new oxicam which has a low COX-2/COX-1 ratio, i.e. it has an inhibitory effect focused on the inflammatory proteins (COX-2) with relative saving of the homeostatic proteins (COX-1). Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 9553452-2 1998 Meloxicam is a new oxicam which has a low COX-2/COX-1 ratio, i.e. it has an inhibitory effect focused on the inflammatory proteins (COX-2) with relative saving of the homeostatic proteins (COX-1). Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 132-137 35008977-7 2022 Schiff base 13, containing 2-bromobenzylidene residue inhibited the activity of both isoenzymes, COX-1 and COX-2 at a lower concentration than standard drugs, and its COX-2/COX-1 selectivity ratio was similar to meloxicam. Meloxicam 212-221 mitochondrially encoded cytochrome c oxidase II Homo sapiens 107-112 15989631-0 1997 Meloxicam: a selective COX-2 inhibitor non-steroidal anti-inflammatory drug. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 23-28 15989631-1 1997 Meloxicam is a new non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits the inducible isoform of the cyclo-oxygenase (COX)-2 enzyme. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 119-142 15989631-4 1997 Only meloxicam and (albeit to a lesser extent) nimesulide could be described as selective for COX-2. Meloxicam 5-14 mitochondrially encoded cytochrome c oxidase II Homo sapiens 94-99 8628979-6 1996 This improved safety profile is likely to be due to meloxicam"s selective inhibition of COX-2 relative to COX-1. Meloxicam 52-61 mitochondrially encoded cytochrome c oxidase II Homo sapiens 88-93 35389917-3 2022 Meloxicam is less selective for COX-2 than celecoxib is and partially inhibits COX-1 at higher doses. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 32-37 35237322-4 2022 Methods: Meloxicam, a COX2 inhibitor with strong anti-HCC potential, was screened from 800 small molecules approved by FDA. Meloxicam 9-18 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-26 9219313-7 1997 NSAIDs that are selective towards COX-2, such as meloxicam, may have an improved side-effect profile over current NSAIDs. Meloxicam 49-58 mitochondrially encoded cytochrome c oxidase II Homo sapiens 34-39 9219316-0 1997 Meloxicam: selective COX-2 inhibition in clinical practice. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 9219316-3 1997 A relatively selective COX-2 inhibitor, such as meloxicam, may combine antiinflammatory efficacy with improved tolerability. Meloxicam 48-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 23-28 9219316-10 1997 In conclusion, relatively selective COX-2 inhibition exemplified by meloxicam may offer effective symptom relief with an improved GI tolerability profile. Meloxicam 68-77 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 9219317-4 1997 Of the drugs investigated in the human whole blood assay, only meloxicam showed selectivity for COX-2 at therapeutically relevant concentrations. Meloxicam 63-72 mitochondrially encoded cytochrome c oxidase II Homo sapiens 96-101 9084574-1 1997 BACKGROUND: Meloxicam is a new NSAID with selectivity for the inducible cyclooxygenase (COX-2) in vitro. Meloxicam 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 88-93 15989563-3 1997 Meloxicam, with some selectivity for COX-2, is already marketed, and at least two companies are carrying out clinical studies with selective inhibitors. Meloxicam 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 8628981-8 1996 The most clinically advanced is meloxicam, which consistently demonstrates higher activity against COX-2 than COX-1 in several test systems. Meloxicam 32-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 99-104 35008977-7 2022 Schiff base 13, containing 2-bromobenzylidene residue inhibited the activity of both isoenzymes, COX-1 and COX-2 at a lower concentration than standard drugs, and its COX-2/COX-1 selectivity ratio was similar to meloxicam. Meloxicam 212-221 mitochondrially encoded cytochrome c oxidase II Homo sapiens 167-172 35070636-0 2022 Synthesis, Spectroscopic and Biological Investigation of a New Ca(II) Complex of Meloxicam as Potential COX-2 Inhibitor. Meloxicam 81-90 mitochondrially encoded cytochrome c oxidase II Homo sapiens 104-109 33348757-8 2020 These findings stay in good correlation with molecular modeling results, which additionally showed that investigated compounds take a position in the active site of COX-2 very similar to Meloxicam. Meloxicam 187-196 mitochondrially encoded cytochrome c oxidase II Homo sapiens 165-170 33266208-8 2020 The TG11 compound, as well as reference meloxicam, turned out to be a preferential COX-2 inhibitor. Meloxicam 40-49 mitochondrially encoded cytochrome c oxidase II Homo sapiens 83-88